Form 13-F position report

RENEO PHARMACEUTICALS INC

Reported by STATE STREET CORPORATION

RPHM CUSIP 75974E103 Manager CIK 0000093751

Reported 0 shares, down 71,636 (100.0%) from the prior quarter.

Reported value -100.0%; share count -100.0% vs. the prior quarter.

Reduced
% of reported 13F value 0 This manager · Q4 2024
Shares 0 Quarter-end amount reported
Reported value $0 Fair value at quarter end
Consecutive quarters held 15 Through Q4 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 753000
2022-03-31 262000
2022-06-30 43000
2022-09-30 55000
2022-12-31 38212
2023-03-31 98072
2023-06-30 1388214
2023-09-30 1660352
2023-12-31 395888
2024-03-31 410734
2024-06-30 108170
2024-09-30 121781
2024-12-31 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

13 quarters
Quarterly reported position history for RENEO PHARMACEUTICALS INC held by STATE STREET CORPORATION.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q4 2024 Reduced 0 -71,636 (-100.0%) 0 $0 2025-02-14
Q3 2024 Unchanged 71,636 0 (0.0%) < 0.01% $121,781 2024-11-14
Q2 2024 Reduced 71,636 -175,794 (-71.0%) < 0.01% $108,170 2024-08-14
Q1 2024 Unchanged 247,430 0 (0.0%) < 0.01% $410,734 2024-05-15
Q4 2023 Added 247,430 +29,393 (13.5%) < 0.01% $395,888 2024-02-14
Q3 2023 Added 218,037 +6,419 (3.0%) < 0.01% $1,660,352 2023-11-14
Q2 2023 Added 211,618 +195,218 (1190.4%) < 0.01% $1,388,214 2023-08-14
Q1 2023 Unchanged 16,400 0 (0.0%) < 0.01% $98,072 2023-05-15
Q4 2022 Unchanged 16,400 0 (0.0%) < 0.01% $38,212 2023-02-14
Q3 2022 Unchanged 16,400 0 (0.0%) < 0.01% $55,000 2022-11-15
Q2 2022 Reduced 16,400 -72,853 (-81.6%) < 0.01% $43,000 2022-08-15
Q1 2022 Added 89,253 +1,190 (1.4%) < 0.01% $262,000 2022-05-16
Q4 2021 Added 88,063 +2,049 (2.4%) < 0.01% $753,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

50 managers reported RENEO PHARMACEUTICALS INC for Q4 2024.

Managers reporting RENEO PHARMACEUTICALS INC in Q4 2024.
Manager Activity Shares Change % of reported 13F Reported value Tenure
NEA Management Company LLC Reduced 0 -4,785,494 0 $0 15 qtrs
TANG CAPITAL MANAGEMENT LLC Reduced 0 -2,946,260 0 $0 5 qtrs
Barclays PLC Reduced 0 -228 0 $0 12 qtrs
AMERIPRISE FINANCIAL INC Reduced 0 -49,824 0 $0 2 qtrs
Shay Capital LLC Reduced 0 -28,617 0 $0 2 qtrs
RENAISSANCE TECHNOLOGIES LLC Reduced 0 -501,534 0 $0 11 qtrs
Carlyle Group Inc Reduced 0 -2,698,957 0 $0 8 qtrs
SIMPLEX TRADING LLC Reduced 0 -100 0 $0 2 qtrs
Russell Investments Group Ltd Reduced 0 -9,520 0 $0 4 qtrs
JPMorgan Chase & Co Reduced 0 -7,668 0 $0 15 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
December 31, 2024
Filed
February 14, 2025
Filing type
13F-HR
Position type
COM

Voting authority reported

No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.